Bazhenova Highlights Treatments for ALK+ NSCLC, Less Common Drivers
Lyudmila A. Bazhenova, MD, discusses treatments for patients with ALK-positive NSCLC, as well as the progress in less common oncogenic drivers, such as NTRK fusions.
Source: OncLive